Immunotherapy Coverage from Every Angle
Advertisement
Advertisement

News

ASTRO 2024: French Trial of Radiotherapy Plus T-DXd in HER2-Positive Breast Cancer
ASTRO 2024: Role of Durvalumab With Radiotherapy for Some With Locally Advanced NSCLC
ESMO 2024: Long-Term Survival Update for INMC Pooled Analysis of Neoadjuvant Therapy in Melanoma
Neoadjuvant/Adjuvant Nivolumab With Chemotherapy Approved for Resectable NSCLC
ASCO Quality 2024: Benefits of Acupuncture in Treating Chemotherapy-Induced Peripheral Neuropathy
ESMO 2024: Hypomethylation Plus Immune Checkpoint Inhibition for Metastatic Melanoma
Can Tusamitamab Ravtansine Improve Survival in CEACAM5-High NSCLC?
ESMO 2024: Chemotherapy-Free Immunotherapy for Immunogenic Triple-Negative Breast Cancer
ESMO 2024: 10-Year Outcomes With Pembrolizumab vs Ipilimumab in Advanced Melanoma
ESMO 2024: Novel EGFR TKI After Amivantamab Therapy for Lung Cancer With EGFR Mutation
ESMO 2024: Supplementary Biomarker Analyses of DAISY Trial of T-DXd in Metastatic Breast Cancer
WCLC 2024: Adding JAK1 Inhibitor to Pembrolizumab in Metastatic PD-L1–Positive NSCLC
ESMO 2024: Adding SBRT to Immunotherapy and Chemotherapy in High-Risk Breast Cancer
Amivantamab Plus Chemotherapy Approved by FDA for NSCLC With Certain Genetic Mutations
ESMO 2024: Immune Checkpoint Inhibition Following Targeted Therapy for Advanced Melanoma
WCLC 2024: Survival Update From TROPION-Lung01 on Dato-DXd vs Docetaxel in NSCLC
ESMO 2024: Final Results From CheckMate 067 of Nivolumab Plus Ipilimumab in Advanced Melanoma
ESMO 2024: Sotigalimab Plus Pembrolizumab in Metastatic Melanoma
ESMO 2024: DESTINY-Breast12 Supports T-DXd in Patients With HER2-Positive Breast Cancer and Brain Metastases
ESMO 2024: 10-Year Trial Update on TILs and Overall Survival in Early-Stage Breast Cancer
WCLC 2024: Ivonescimab vs Pembrolizumab in First-Line Treatment of PD-L1–Positive NSCLC
WCLC 2024: Immunotherapy Before and After Surgery for NSCLC
Long-Term Health-Related Quality of Life With Adjuvant Pembrolizumab in Stage III Melanoma
Novel Triplet Under Study for Metastatic NSCLC: Early Phase II Results
Survival Outcomes in BRAF-Mutant Melanoma: BRAF/MEK vs PD-1 Inhibitors
Atezolizumab Before and After Chemoradiation: Novel Plan for Unresectable Stage III NSCLC
Early Results of Combination Regimens With Pembrolizumab in Melanoma
4-Year Follow-up on Lenvatinib Plus Pembrolizumab in Advanced Melanoma
Chemotherapy-Free Combination Approved by FDA for EGFR-Mutated NSCLC
How Intratumoral Bacteria Might Improve Outcomes With Immunotherapy for NSCLC
Nivolumab Plus Relatlimab in Melanoma: 3-Year Survival Outcomes From RELATIVITY-047
FDA Approves Use of Durvalumab With Chemotherapy Before and After Surgery in NSCLC
Novel Immunotherapy Combination After Anti–PD-1 Therapy Fails in Advanced Melanoma
Copyright © 2024 National Comprehensive Cancer Network, All Rights Reserved
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.